Atara Biotherapeutics Inc (ATRA) has disclosed a new risk, in the Manufacturing category.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The analyst notes that Atara Biotherapeutics Inc. faces significant manufacturing risks as it integrates complex, partially undocumented processes and inventory obtained from partners, raising the possibility of gaps in transferred know-how and historical regulatory compliance. Any failure to demonstrate comparability across facilities, or to scale these intricate cell therapy processes to commercial standards, could delay product development and constrain supply.
He observes that the company’s dependence on specialized raw materials, leukapheresis collections, and highly trained personnel exposes it to disruptions from pandemics, supply shortages, and operational failures, as illustrated by past contamination issues at a contract manufacturing organization. Such events can trigger lot failures, inventory write‑offs, regulatory holds, and reputational damage, ultimately limiting Atara’s ability to meet clinical and commercial demand for its therapies.
The average ATRA stock price target is $15.50, implying 47.90% upside potential.
To learn more about Atara Biotherapeutics Inc’s risk factors, click here.